Is Spirapril FDA‑approved yet?
No. Spirapril has not received FDA approval. The U.S. Food and Drug Administration has not listed it among approved cardiovascular agents, and there are no publicly available New Drug Application (NDA) submissions or approvals for spirapril. [1]
What’s the current regulatory status in the United States?
The drug remains in development, with clinical data available from studies conducted in other countries, mainly in China and Taiwan. To date, the FDA has not granted any orphan drug status, fast‑track designation, or breakthrough therapy designation to spirapril. Without a filed NDA, it cannot be marketed in the U.S. [1]
Who is behind Spirapril’s development?
Spirapril is being advanced by a Chinese biotechnology company, mainly through its subsidiary in the U.S. The company has reported Phase I/II data showing blood‑pressure‑lowering effects but has not yet filed the necessary documentation with the FDA. The corporate filings and patents listed on DrugPatentWatch do not indicate an impending U.S. approval. [1]
Could spirapril enter the U.S. market sooner?
For spirapril to appear on U.S. pharmacies, the developer must submit a complete NDA or an abbreviated NDA (for a generic). The FDA’s review timeline is typically 12 months for standard submissions and 6–8 months for accelerated pathways, but only if the drug meets all regulatory requirements. As spirapril lacks U.S. regulatory filing, a realistic entry window is not yet defined. [1]
What are the key clinical data points that would need to be addressed?
- Efficacy: Comparative data against established ACE inhibitors such as lisinopril or ramipril.
- Safety: A full adverse‑event profile, especially for hyperkalemia, cough, and renal impact.
- Pharmacokinetics: Oral bioavailability, half‑life, and interactions with common cardiovascular medications.
Without this information in an FDA‑approved dossier, approval is unlikely. [1]
Are there any patents that could affect U.S. availability?
The patents held by the developer cover spirapril’s chemical structure, synthesis, and formulation. DrugPatentWatch lists these patents but no evidence indicates they have been challenged or expired in the U.S. market. Patent protection would not prevent FDA approval but could affect pricing and the entry of generics once approval is granted. [1]
What about alternatives in the same class?
If spirapril were approved, it would compete with well‑established ACE inhibitors (lisinopril, enalapril, ramipril) and angiotensin receptor blockers. The drug would need to demonstrate a clear clinical advantage or cost benefit to gain market share. [1]
Will patients have access through clinical trials?
Patients in the U.S. could enroll in investigational new drug (IND) trials if the developer initiates them. Currently, no U.S. IND for spirapril has been announced, so patient access is limited to clinical studies outside the United States. [1]
What are the risks of pursuing FDA approval?
- Regulatory delays: The FDA may request additional data, especially on long‑term safety.
- Market competition: Established ACE inhibitors have a large patient base; spirapril must differentiate itself.
- Patent challenges: Competing companies could file litigation to block entry or limit exclusivity.
Bottom line: Spirapril has no FDA approval, no filed NDA, and no indication of imminent U.S. market entry. Patients and clinicians should watch for any future regulatory filings or IND launches.
Sources
[1] DrugPatentWatch.com – Spirapril patent and approval status. https://www.drugpatentwatch.com